Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2009 1
2016 1
2018 2
2019 2
2020 2
2022 1
2023 9
2024 5
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean m moghaddasi (7 results)?
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A,… See abstract for full author list ➔ Parsons MT, et al. Hum Mutat. 2019 Sep;40(9):1557-1578. doi: 10.1002/humu.23818. Hum Mutat. 2019. PMID: 31131967 Free PMC article.
Structural basis for varying drug resistance of SARS-CoV-2 M(pro) E166 variants.
Esler MA, Shi K, Rollie JA, Delgado R, Vishwakarma J, Dabrowska A, Prahlad J, Moghadasi SA, Harris RS, Aihara H. Esler MA, et al. mBio. 2025 Jul 9;16(7):e0262424. doi: 10.1128/mbio.02624-24. Epub 2025 Jun 2. mBio. 2025. PMID: 40454888 Free PMC article.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M(pro)) has an essential role in the virus lifecycle and, accordingly, it is a target for antiviral drugs. ...These studies shed light on the molecular mechanisms of a key M(pro) drug resist …
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M(pro)) has an essential role in the virus lifecycle and, …
SARS-CoV-2 M(pro) inhibitor identification using a cellular gain-of-signal assay for high-throughput screening.
Delgado R, Vishwakarma J, Moghadasi SA, Otsuka Y, Shumate J, Cuell A, Tansiongco M, Cooley CB, Chen Y, Dabrowska A, Basu R, Anindita PD, Luo D, Dosa PI, Harki DA, Bannister T, Scampavia L, Spicer TP, Harris RS. Delgado R, et al. SLAS Discov. 2024 Sep;29(6):100181. doi: 10.1016/j.slasd.2024.100181. Epub 2024 Aug 22. SLAS Discov. 2024. PMID: 39173830 Free PMC article.
Here, we report the results of a high-throughput screen of 649,568 compounds using a cellular gain-of-signal assay. In this assay, M(pro) inhibits expression of a luciferase reporter, and 8,777 small molecules were considered hits by causing a gain in luciferase activity 3 …
Here, we report the results of a high-throughput screen of 649,568 compounds using a cellular gain-of-signal assay. In this assay, M( …
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M(pro)/3CL(pro) in Living Cells.
Moghadasi SA, Esler MA, Otsuka Y, Becker JT, Moraes SN, Anderson CB, Chamakuri S, Belica C, Wick C, Harki DA, Young DW, Scampavia L, Spicer TP, Shi K, Aihara H, Brown WL, Harris RS. Moghadasi SA, et al. mBio. 2022 Jun 28;13(3):e0078422. doi: 10.1128/mbio.00784-22. Epub 2022 Apr 26. mBio. 2022. PMID: 35471084 Free PMC article.
The main protease, M(pro), of SARS-CoV-2 is required to cleave the viral polyprotein into precise functional units for virus replication and pathogenesis. ...IMPORTANCE The main protease, M(pro), of SARS-CoV-2 is an essential viral protein required for the earliest …
The main protease, M(pro), of SARS-CoV-2 is required to cleave the viral polyprotein into precise functional units for virus replicat …
A comprehensive study of SARS-CoV-2 main protease (M(pro)) inhibitor-resistant mutants selected in a VSV-based system.
Costacurta F, Dodaro A, Bante D, Schöppe H, Sprenger B, Moghadasi SA, Fleischmann J, Pavan M, Bassani D, Menin S, Rauch S, Krismer L, Sauerwein A, Heberle A, Rabensteiner T, Ho J, Harris RS, Stefan E, Schneider R, Kaserer T, Moro S, von Laer D, Heilmann E. Costacurta F, et al. bioRxiv [Preprint]. 2023 Oct 4:2023.09.22.558628. doi: 10.1101/2023.09.22.558628. bioRxiv. 2023. Update in: PLoS Pathog. 2024 Sep 11;20(9):e1012522. doi: 10.1371/journal.ppat.1012522. PMID: 37808638 Free PMC article. Updated. Preprint.
This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M(pro) resistance mutations, we passaged a previously developed, chimeric vesicular stomatitis virus (VSV-M(pro)) with increasing, yet suboptimal conce …
This study aimed to identify and characterize mutations that confer resistance to nirmatrelvir. To safely generate M(pro) resistance …
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
Moghadasi SA, Biswas RG, Harki DA, Harris RS. Moghadasi SA, et al. bioRxiv [Preprint]. 2023 Feb 27:2023.02.25.530000. doi: 10.1101/2023.02.25.530000. bioRxiv. 2023. PMID: 36909573 Free PMC article. Updated. Preprint.
Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. ...
Here a panel of SARS-CoV-2 main protease (M(pro)) variants and a robust cell-based assay are used to compare the resistance profiles …
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
Moghadasi SA, Biswas RG, Harki DA, Harris RS. Moghadasi SA, et al. NPJ Antimicrob Resist. 2023 Aug 20;1(1):9. doi: 10.1038/s44259-023-00009-0. NPJ Antimicrob Resist. 2023. PMID: 39843958 Free PMC article.
Here a robust cell-based assay is used to determine the relative potencies of nirmatrelvir, ensitrelvir, and FB2001 against a panel of SARS-CoV-2 main protease (M(pro)) variants. The results reveal that these three drugs have at least partly distinct resistance mutation pr …
Here a robust cell-based assay is used to determine the relative potencies of nirmatrelvir, ensitrelvir, and FB2001 against a panel of SARS- …
28 results